Ratings by JPMorgan (Priyanka Grover)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/18/2026 | Mereo BipPharma Group | MREO | Downgrade | Underweight (Neutral) |
0.31 (0.28) |
-9.68% | Details | |
| 8/18/2026 | Nuvation Bio Inc | NUVB | New Coverage | Overweight (N/A) |
6.22 (6.64) |
6.75% | Details | |
| 8/14/2026 | BridgeBio Oncology Therapeutics, In | BBOT | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/14/2026 | Relay Therapeutics | RLAY | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/7/2026 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/27/2026 | Rhythm Pharmaceuticals | RYTM | New Coverage | Overweight (N/A) |
102.66 (104.74) |
2.03% | Details | |
| 7/8/2026 | BridgeBio Oncology Therapeutics, In | BBOT | New Coverage | Overweight (N/A) |
8.41 (8.82) |
4.88% | Details | |
| 7/8/2026 | Relay Therapeutics | RLAY | New Coverage | Overweight (N/A) |
18.90 (18.49) |
-2.17% | Details | |
| 4/30/2026 | Recursion Pharmaceuticals | RXRX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/23/2026 | Mereo BipPharma Group | MREO | Downgrade | Neutral (Overweight) |
0.36 (0.31) |
-13.89% | Details | |
| 12/17/2025 | Recursion Pharmaceuticals | RXRX | Upgrade | Overweight (Neutral) |
4.20 (3.33) |
-20.71% | Details | |
| 8/25/2025 | Mereo BipPharma Group | MREO | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/10/2025 | Mereo BipPharma Group | MREO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/27/2025 | Mereo BipPharma Group | MREO | New Coverage | Overweight (N/A) |
2.35 (0.36) |
-84.68% | Details |
